

tyco
Healthcare

Mallinckrodt

J007 Rec'd PCT/PTO 0 4 APR 2005

Docket: 1592 WO/US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mertens

Serial No.: 10/523,184


Filed: 28 Jan 2005

Title: Radioactively Labelled Amino Acid Analogues, their Preparation and Use

I hereby certify that this correspondence is being deposited
with the United States Postal Service as first class mail in an
envelope addressed to Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450

on 4-1-05

(Date of Deposit)



Barbara A. Krisch


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 CFR 1.56 and 1.97, please find enclosed a completed Forms
PTO/SB/08A and 08B (4 pages). The U.S. Patent and Trademark Office is respectfully
requested to consider and make of record these documents.

Respectfully submitted,



Jerad G. Seurer
Attorney for Applicant
Reg. No. 45,467

Page 2 (1592 WO/US) USSN 10/523,184)

Mallinckrodt Inc.
675 McDonnell Boulevard
P.O. Box 5840
St. Louis, Missouri 63134
Phone: 314-654-3814
Fax: 314-654-3156
31 March 2005



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Application Number	10/523184
Filing Date	28-Jan-2005
First Named Inventor	Mertens
Art Unit	
Examiner Name	
Attorney Docket Number	1592 WO/US


[illegible]

FOREIGN PATENT DOCUMENTS						T ⁶
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
		WO 03/099746 A1	12-04-2003	ABX GMBH		
		GB 1220591 A	01-27-1971	Pierre Crooij		
		GB 2020275 A	11-14-1979	Henning Berlin		
		FR 1581.849 A	09-19-1969	Aktiebolaget		

Date	
Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/1-01

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

Application Number

10/523184

Filing Date

28-Jan-2005

First Named Inventor

Mertens

Art Unit

Examiner Name

Attorney Docket Number

1592 WO/US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DEEHAN, B et.al. "Uptake and Distribution of L-3-I-125 Lodo-alpha-methyl tyrosine in exp. rat..." Euro.J.of Nuc. Med., Feb.,1993, pg. 101-106,Vol. 20, no. 2, Berlin, DE	
		WESTER H.J. et.al. "Synth. and Radi. of O-(¹⁸ F)fluorethyl)-L-tyrosine for tum. imag.", J. of Nuc. Med.: Off. Publ., Soc. of Nuc.Med.,Jan,1999,pp.205-212,Vol. 40,no.1	
		ISHIWATA K. et.al.:"Synth. and Rad. Dos. of 4-Borono-2-(¹⁸ F)Fluoro...", Intl. Jnl. of Rad., June 25, 1990, pp. 325-328, vol. 42, no. 2, Pergamon PressLTD, GB	
		KAWAI K et. al."Monoiodo-D-Tyrosine, an artif. Amino Acid...", Nuc. Med. and Bio., 1990, pp. 369-376, vol. 17, no. 4, Pergamon, Oxford, GB	
		BERGSTROM, et.al."PET study of methionine accum. in glioma...", Jnl of Comp. Assist. Tomagraphy, 1987,pp.208-213,Vol. 11, no. 2,Raven Press, NY	
		COENEN, et.al."Cerebral metabolism of L-2- ¹⁸ F-...", J. Nucl. Med., Aug, 1989, pp.1367-1372, Vol.30,no.8	
		BIERSACK, et. al."Imaging of brain tumors with L-3-[¹²³ I]-iodo...", J. Nucl. Med., 1989, pp.110-112, Vol.30	
		JAGER, P.L.et.al., "Uptake mechanism of L-3-[¹²⁵ I]iodo-alpha-methyl-..."Nuc. Med. Comm., 2001,pp.87-96,Vol.22, no.1, Lippincott Williams & Wilkins	
		LAHOUTTE, et.al."In vitro charac. of the influx of 3-[¹²⁵ I]iodo-...", Nuc. Med. of Bio., 2001,pp.129-134, Vol. 28,Elsevier Science Inc.	
		HEISS, et.al."Invest. of transport mech. and uptake kinetics of O-2-[¹⁸ f]fluoroethyl)-L-...", J. Nuc. Med., 1999,pp. 1367-1373, Vol. 40	

Examiner
Signature

Date


Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/523184
Filing Date	28-Jan-2005
First Named Inventor	Mertens
Art Unit	
Examiner Name	
Attorney Docket Number	1592 WO/US

Sheet 3 of 4

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VEKEMAN, et.al., "L-[2-radioiodo]Tyrosine, a new potential protein synthesis...", Eur. J. Nuc. Med., 1999, pp.971, Vol.26, no.9,	
		MERTENS, et.al."Uptake study of L-2-I251-o-Tyrosine, ..."Eur. J. Nuc. Med., 2000, p.1063, Vol. 27	
		MERTENS, et.al."New approach of cell uptake kinetics of L-2-123I-Tyr...", Eur. J. Nuc. Med. Mol. Imag., 2002, p.S377-P722, Vol. 29	
		SAMNICK, et.al."Initial evaluation on the feasibility of SPECT with p-iodo-L-phenylalanine...", Nuc. Med. Com., 2002, pp. 121-130, Vol. 23, no.2, Lippincott Williams & Wilkins	
		RAU, et.al."O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET):a tracer for differentiation...", Eur. J. Nuc. Med. Mol. Imag., 2002, pp.1039-1046, Vol. 29, no.8, Springer-Verlag	
		WESTER, et.al."Synthesis and Radiopharm.of O-(2-[18F]fluoroethyl)-L...", J. Nucl. Med., 1999, pp. 205-212, Vol. 40	
		MERTENS, et.al."Synthesis, radiosynthesis and in vitro charac...", Nuc. Med. Bio., 2004, pp.739-746, Vol. 31, Elsevier Inc.	
		MERTENS, et.al."L-[2-Radioiodo]-Tyrosine a potential tumour tracer for SPECT...", J. of Label.Comp. and Radiopharm., May, 2001, pp.S860-S862, Vol.44(Suppl. 1)	
		HAMACHER, et.al."Efficient routine production of the 18F-labelled...", Applied Rad. and Isotopes, 2002, pp.853-856, Vol.40(issue 6), Elsevier Science, Ltd.	
		HAMACHER, et.al."Convenient synth. of n.c.a. O-(2-[18F]Fluoroethyl)-...", J. Labelled Cpd. Radiopharm., 2001, p.S855, Vol. 44	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

4

Application Number

10/523184

Filing Date

28-Jan-2005

First Named Inventor

Mertens

Art Unit

Examiner Name

Attorney Docket Number

1592 WO/US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LAHOUTTE, et.al."Comparative Biodistrib. of Iodinated Amino Acids in Rats:...",Biodistrib.of Iodinated Aminos Acids, 2003,pp.1489-1494,Vol.44, no. 9	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.